Cardiac Rhythm Management Devices – Market Insights – United States

The US CRM device market is expected to grow rapidly through 2034, driven by the increasing adoption of innovative devices, such as dual-chamber leadless pacemakers and extravascular ICDs. These new product innovations, supported by positive clinical evidence, are driving market growth, with these devices gaining traction as the new standard of care.

This Medtech 360 Report provides comprehensive data and analysis on the state of the US cardiac rhythm management device market from 2019 through 2034.

The adoption of innovative devices will drive growth in the US CRM device market.

What level of growth is forecasted for novel devices like dual-chamber leadless pacemakers and extravascular ICDs? How will their adoption impact the revenues of traditional CRM devices and other related device segments?

What factors are likely to influence the uptake of dual-chamber leadless pacemakers and extravascular ICDs?

How have clinical trials supported the approval and uptake of novel CRM devices?

The generation of clinical data will be an important competitive factor for disruptive CRM devices.

Which clinical trials are ongoing in the CRM market and may lead to new approvals or indication expansions?

Which regulatory and reimbursement changes are expected due to clinical evidence?

How has clinical data offset negative press and physician perception of market competitors?

How will the market share dynamics of different device segments be altered by ongoing clinical trials?

Some segments of the CRM device market are mature and highly saturated, spurring competitors to innovate to achieve growth.

How can individual competitors realize growth in this large but saturated market?

How do epidemiological trends and new technologies influence growth in different product segments?

How will the market change with the recent approval of the first leadless dual-chamber pacemaker?

Will mergers and acquisitions play a key role in this device market?